Nanomedicine-Based Strategies to Target Chronic Inflammation in Obesity-Driven Type 2 Diabetes

Bwanbale Geoffrey David

Faculty of Pharmacy Kampala International University Uganda

                                                                                                 ABSTRACT
Obesity-driven type 2 diabetes (T2D) is sustained by chronic, low-grade inflammation that disrupts insulin signaling across adipose tissue, liver, skeletal muscle, and vascular beds. Hypertrophic adipocytes and stromal immune cells form an inflammatory niche characterized by cytokine secretion, lipotoxic stress, hypoxia, and extracellular matrix remodeling. Conventional anti-inflammatory agents can improve insulin sensitivity but are limited by off-target toxicities, short half-lives, and inadequate delivery to diseased depots. Nanomedicine offers a precision toolkit to overcome these barriers by concentrating therapeutics in inflamed tissues, enabling intracellular delivery to key immune populations, coordinating controlled and stimuli-responsive release, and coupling therapy with imaging for on-treatment monitoring. This review synthesizes mechanistic
underpinnings of metabolic inflammation; design principles for adipose- and liver-homing nanoparticles; smallmolecule, biologic, and nucleic acid payloads that reprogram innate and adaptive immune tone; and theranostic approaches for quantifying target engagement. We discuss safety, manufacturability, and regulatory considerations unique to chronic metabolic indications and propose clinical trial frameworks that integrate
continuous glucose monitoring with inflammatory biomarkers and organ-level imaging. By aligning materials science with immunometabolic biology, nanomedicine can convert broad immunosuppression into tissue- and pathway-selective modulation, improving insulin sensitivity while minimizing systemic risk.

Keywords: metabolic inflammation; nanomedicine; adipose tissue; macrophages; cytokines; insulin resistance;
lipid nanoparticles; nucleic acid therapeutics; theranostics; type 2 diabetes

CITE AS: Bwanbale Geoffrey David. (2026). NanomedicineBased Strategies to Target Chronic Inflammation in Obesity-Driven Type 2 Diabetes. NEWPORT INTERNATIONAL JOURNAL OF PUBLIC HEALTH AND PHARMACY,7(1):87-94.
https://doi.org/10.59298/NIJPP/2026/718794